Comparison of the preventive effects of Apixaban and Enoxaparin on the postoperative vascular thromboembolism

Comparison of the preventive effects of Apixaban and Enoxaparin on the postoperative vascular thromboembolism in patients undergoing surgery with gynecological and colorectal cancers

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230419057967N1

Enrollment

160

Registered

2023-12-09

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous embolism and thrombosis. Other venous embolism and thrombosis

Interventions

Intervention 1: Intervention group: 5000 units of Heparin (Caspiantamin, Iran) are injected 30 minutes before skin incision, subcutaneously. 18 to 24 hours after the termination of the operation, 0.5

Eligibility

Sex/Gender

All

Age

18 Years to 89 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with gynecological or colorectal cancers (rectum and colon) undergo laparotomy.

Exclusion criteria

Exclusion criteria: Use of non-steroidal anti-inflammatory drugs for more than one year Having other types of cancers History of thromboembolism Having severe kidney or liver diseases Having coagulation or bleeding disorders Using thrombogenic drugs Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
The occurrence of major bleeding including hematoma and pelvic and abdominal bleeding. Timepoint: Three times, 30, 60 and 90 days after surgery. Method of measurement: Clinical symptoms and paraclinical findings.;Non-major bleeding incidence with clinical significance (requiring intervention). Timepoint: Three times, 30, 60 and 90 days after surgery. Method of measurement: Clinical symptoms and paraclinical findings.	—

Measure

Time frame

The occurrence of major bleeding including hematoma and pelvic and abdominal bleeding. Timepoint: Three times, 30, 60 and 90 days after surgery. Method of measurement: Clinical symptoms and paraclinical findings.;Non-major bleeding incidence with clinical significance (requiring intervention). Timepoint: Three times, 30, 60 and 90 days after surgery. Method of measurement: Clinical symptoms and paraclinical findings.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarima Takizad

Bagheiat-allah University of Medical Sciences

farimatakizad@yahoo.com+98 21 8805 0436

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026